Diane Brady talks to Pfizer CEO Albert Bourla about defending science amid a backdrop of political threats. The big story: ...

Unlike other companies grappling with evolving trade policy, Pfizer didn't revise its full-year outlook Tuesday.

Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

Pfizer Inc. (NYSE: PFE) chief executive Albert Bourla says uncertainty related to higher tariffs on pharmaceutical imports ...

For years, Pfizer was the only drugmaker with treatments for the disease, called ATTR-CM, but BridgeBio’s CEO said in an ...

Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations ...

CEO Albert Bourla is waiting for the US government to finalize its decision on whether to place a 25% tariff on ...

Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Pfizer is raising the bar for its sweeping cost-savings drive yet again, this time cranking up the total target to $7.7 ...

Like his Big Pharma peers, Pfizer (PFE) CEO Albert Bourla is waiting for the US government to finalize its decision on whether to place a 25% tariff on pharmaceutical imports. To be sure ...